BioNTech SE BNTX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$86.90 up $1.04, 1.21% on Nov 6
Last price · Previous close $85.86
- Market cap
- At the last price
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$6.77Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$86.90up $1.04, 1.21%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$85.86Nov 5
- Volume1.19MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.16MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $79.52 to $124.00; now $86.90
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
BNTX trailed the S&P 500 in all 6 periods.
| Period | BNTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BNTX: down 9.2% S&P 500: down 5.6% | BNTX trailed the S&P 500 by 3.6 percentage points Trailed |
| 3M | BNTX: down 4.7% S&P 500: down 4.1% | BNTX trailed the S&P 500 by 0.6 percentage points Trailed |
| YTD | BNTX: down 8.7% S&P 500: up 8.7% | BNTX trailed the S&P 500 by 17.4 percentage points Trailed |
| 1Y | BNTX: down 15.9% S&P 500: up 10.9% | BNTX trailed the S&P 500 by 26.8 percentage points Trailed |
| Long term | ||
| 3Y | BNTX: down 12.9% S&P 500: up 75.0% −4.5% vs +20.5% a year | BNTX trailed the S&P 500 by 87.9 percentage points Trailed |
| 5Y | BNTX: down 59.0% S&P 500: up 67.8% −16.3% vs +10.9% a year | BNTX trailed the S&P 500 by 126.8 percentage points Trailed |
$10,000 invested in BNTX 5 years ago (Nov 5, 2021) would be worth about $4,103 as of , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
BNTX trailed the S&P 500 in all 6 periods.
| Period | BNTX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BNTX: down 9.2% S&P 500: down 5.6% | BNTX trailed the S&P 500 by 3.6 percentage points Trailed |
| 3M | BNTX: down 4.7% S&P 500: down 4.3% | BNTX trailed the S&P 500 by 0.4 percentage points Trailed |
| YTD | BNTX: down 8.7% S&P 500: up 7.8% | BNTX trailed the S&P 500 by 16.5 percentage points Trailed |
| 1Y | BNTX: down 15.9% S&P 500: up 9.7% | BNTX trailed the S&P 500 by 25.6 percentage points Trailed |
| Long term | ||
| 3Y | BNTX: down 12.9% S&P 500: up 68.8% −4.5% vs +19.1% a year | BNTX trailed the S&P 500 by 81.7 percentage points Trailed |
| 5Y | BNTX: down 59.9% S&P 500: up 56.9% −16.7% vs +9.4% a year | BNTX trailed the S&P 500 by 116.8 percentage points Trailed |
$10,000 invested in BNTX 5 years ago (Nov 5, 2021) would be worth about $4,011 as of , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$447.23
Closing high on . Now 80.6% below that record.
Split-adjusted daily closes since Oct 10, 2019.
Stock splits
BNTX hasn’t split since its price history begins in 2019.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $2.78Bdown 21.1%
- Net income
- −$1.70B
- Diluted EPS
- −$6.77
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $1.24B | $270.03M | $1.10 |
| Q1 FY25 (Mar 31, 2025) | $197.84M | −$450.00M | −$1.87 |
| Q2 FY25 (Jun 30, 2025) | $306.82M | −$454.82M | −$1.88 |
| Q3 FY25 (Sep 30, 2025) | $1.78B | −$33.69M | −$0.14 |
| Q4 FY25 (Dec 31, 2025) | $1.07B | −$358.40M | −$1.47 |
| Q1 FY26 (Mar 31, 2026) | $136.69M | −$615.63M | −$2.43 |
| Q2 FY26 (Jun 30, 2026) | $120.55M | −$936.99M | −$3.70 |
| Q3 FY26 (Sep 30, 2026) | $1.46B | $208.95M | $0.83 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $21.49B | $11.66B | $44.88 |
| FY22 (Dec 31, 2022) | $18.45B | $10.06B | $40.27 |
| FY23 (Dec 31, 2023) | $4.23B | $1.03B | $4.24 |
| FY24 (Dec 31, 2024) | $2.86B | −$692.30M | −$2.88 |
| FY25 (Dec 31, 2025) | $3.37B | −$1.34B | −$5.52 |
Margins
- Gross 74.8%
- Operating −75.6%
- Net −61.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$490.84MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$258.59MLast 12 months
- Capital spending$232.25MLast 12 months
- −17.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- Not reportedLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $18.56BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$690.71MAs of Sep 30, 2026
- Net cash$17.87BAs of Sep 30, 2026
- 8.55As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.03As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −8.1%Last 12 months
Over the last 12 months, BioNTech lost money: its net loss was 8.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −7.1%Last 12 months
Over the last 12 months, BioNTech’s net loss was 7.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.000 |
| 2017 | $0.000 |
| 2018 | $0.000 |
| 2019 | $0.000 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $3.65 |
| 2023 | $0.000 |
| 2024 | $0.000 |
| 2025 | $0.000 |
| 2026 (to date) | $0.000 |
Dividend details
- $0.00Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- Dividend yield0.00%Last 12 months
- $2.11Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
About BioNTech SE
BioNTech SE ADS
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Germany
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
BNTX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
BNTX stock FAQ
What is BNTX stock’s price today?
BioNTech (BNTX) traded at $86.90 as of , up $1.04 (1.21%) from the previous close of $85.86. Over the past 52 weeks it has traded between $79.52 and $124.00.
If you invested $1,000 in BNTX 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in BNTX on would be worth about $410 as of , a total return of −59.0%. The same $1,000 would be worth $841 if invested one year ago. Past performance doesn’t predict future returns.
What is BNTX’s P/E ratio?
BNTX’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$6.77).
How much revenue does BioNTech make?
BioNTech reported $2.8 billion of revenue over the four quarters to , down 21.1% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $1.5 billion, down 18.1% from a year earlier.
Is BioNTech profitable?
Not over the four quarters to . BioNTech reported a net loss of $1.7 billion across those four quarters on $2.8 billion of revenue.
What are BNTX’s earnings per share?
BNTX’s diluted earnings per share were −$6.77 over the four quarters to , compared with −$2.79 in the twelve months before. The latest quarter (Q3 FY26) brought $0.83 per share, against −$0.14 a year earlier (how EPS works).
Does BNTX pay a dividend?
BioNTech hasn’t paid a dividend in the last twelve months.
What is BNTX’s 52-week high and low?
Over the past 52 weeks BNTX has traded as low as $79.52 and as high as $124.00. At $86.90 as of , it is 29.9% below that high and 9.3% above the low.
What is BNTX’s all-time high?
BNTX’s highest closing price was $447.23 on , adjusted for stock splits. At $86.90 as of , it is 80.6% below that record.
Has BNTX stock ever split?
No. BNTX hasn’t split since its price history begins in 2019.
How has BNTX stock performed?
Including dividends and measured to the last price on , BNTX has returned −8.7% so far this year and −15.9% over the past year, and −59.0% over five years (−16.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is BioNTech in?
BioNTech is in the Healthcare sector and the Biotechnology industry, and is headquartered in Germany.
What exchange does BNTX trade on?
BioNTech trades on the Nasdaq under the ticker symbol BNTX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.